NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies.

STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response.

The technology effectively converts a weak immune response against the tumor to a powerful yet safe native antibacterial immune reaction.The company's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors.